You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Type 1 Issues Articles
Popular Type 1 Issues Articles
Highly Recommended Type 1 Issues Articles
Send a link to this page to your friends and colleagues.
The Food and Drug Administration (FDA) has launched a "Bad Ad Program," an outreach effort aimed at educating healthcare providers and urging them to report misleading drug advertisements. The Division of Drug Marketing, Advertising, and Communications (DDMAC), in the FDA's Center for Drug Evaluation and Research, administers the program.
The program will help healthcare providers recognize misleading drug promotion and provide them with a simple way to report back to the agency.
About $4 billion out of a $20 billion advertising budget goes toward patient-targeted advertisements. Some drug industry critics feel that TV drug ads emphasize the benefits of the medication and minimize the risks.
According to FDA regulations:
Prescription drug advertising must:
What types of promotion does DDMAC regulate?
DDMAC does not regulate promotion of:
As part of its new program, FDA will offer doctors training at medical conferences to help spot misleading ads. They can report advertising violations anonymously by e-mailing firstname.lastname@example.org or calling 877-RX-DDMAC.
* * *
The FDA's Bad Ad Program: http://www.fda.gov/badad
0 comments - May 13, 2010
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.